Des Plaines, IL 60016, US
Biotechnology
www.abbott.com
Abbott Molecular Inc., a genomic disease management company, engages in the development and marketing of clinical laboratory products, which provide information critical to the evaluation and management of cancer, prenatal disorders, and other genetic diseases. It currently markets seven U.S. Food and Drug Administration or foreign cleared or approved clinical products in addition to distributing over 300 Analyte Specific Reagent and research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 59 countries. The company was founded in 1991 and is based in Des Plaines, Illinois. As on 12/05/2001, Abbott Molecular Inc. operates as a subsidiary of Abbott Laboratories Inc.
Mary Szela joined Melinta Therapeutics as Chairperson in January of 2013 and was named Chief Executive Officer in April of 2013. Ms. Szela is an accomplished pharmaceutical executive with a 25-year history of consistently creating growth, generating positive organizational change and inspiring high-performing teams. Most recently, she was Senior Vice President, global strategic marketing and services in the Abbott Laboratories Pharmaceutical Products Group. In this role, Ms. Szela licensed and acquired seven high-quality NMEs adding $7 billion in pipeline potential.
Previously, she was the Senior Vice President, U.S. Pharmaceuticals at Abbott Laboratories – an $8 billion business. From 2001 to 2008, she directed the development, launch and growth of more than eight new pharmaceutical products, including Abbotts flagship product, Humira. During her tenure, she oversaw the approval and successful launch of multiple new indications for Humira and drove more than $1.
Patrick J. Sullivan is the Board Director at PerkinElmer Inc.
Age 61; Principal Occupation: Retired Executive Chairman of Hologic, Inc., a womens health diagnostic and medical device company.
Director of PerkinElmer since 2008. Member of the audit and compensation and benefits committees.
Mr. Sullivan served as Executive Chairman and a Director of Hologic from its merger with Cytyc Corporation in October 2007 until May 2008, having previously served Cytyc as,
Chief Executive Officer,
Director since March 1994,
Vice Chairman of the board of directors since January 2001,
Chairman-elect since January 2002,
Chairman since May 2002 .
From March 1994 to January 2002, and from July 2002 to October 2007, Mr. Sullivan also served as President of Cytyc.
From January 1991 to March 1994, as Vice President of Sales and Marketing.
Prior to joining Cytyc, Mr.
Robert Kamen is interim chief technology officer of Jounce Therapeutics and entrepreneur-in-residence of Third Rock Ventures. He joined Third Rock Ventures in 2010, bringing with him more than 30 years of experience in the pharmaceutical and biotechnology industries.
Most recently, he served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira, the first fully human antibody to achieve marketing approval in the U.S. and Europe, and was a member of the Abbott Pharmaceuticals Executive Management Committee. Dr. Kamen also served as the president of BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001.
Earlier in his career, Dr. Kamen led discovery at Genetics Institute, Inc. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, acquired by Cephalon in 2010. Dr. Kamen serves as a director of Harbour Antibodies BV, Lycera Corp.
Mr. Silverman is the former CEO of mtm laboratories AG, an in-vitro diagnostics company which developed and commercialized a portfolio of products using its patent protected biomarkers for early detection and diagnosis of cervical cancer.
He was instrumental in building this company into a global, fully integrated business, with a strong foundation of significant clinical utility and commercial momentum. Mr. Silverman successfully negotiated the purchase of mtm by Roche Diagnostics in August 2011 for a total deal value of $270 Million and then facilitated the integration of mtm into Roche.
Prior to mtm laboratories, Mr. Silverman was the Senior Vice-President of Worldwide Commercial Operations for Viacell, a company focused on developing stem cell therapies and cord blood banking. Before this, he spent 6 years with Cytyc Corporation.
Charles founded Sonoma Orthopedic Products, Inc. with two colleagues in 2006. fCharles has led design and development teams in the medical device market for over twenty-five years at Abbott Stryker Corporation, and Bristol Myers. He is the named inventor on thirty-five patents and patent applications. He was responsible for the design teams at Therasense, Inc. (now part of Abbott Diabetes Care). His other product experience include: co-inventor an emerging world, rapid agglutination analysis device, autologous fibrin adhesive systems, and portable, hospital-based pharmaceutical delivery systems. Charles holds a Bachelor of Science degree in Chemical Engineering from Purdue University and Master of Science degree in Materials Engineering from Northwestern University.
Paul N. Clark is an Operating Partner and Strategic Advisory Board member of Genstar Capital LLC.
He is responsible for expanding Genstars life sciences practice.
Paul was Director, CEO and President of ICOS Corporation from 1999 until the sale to Eli Lilly and Company in 2007. He also served as Chairman from 2000 until 2007. ICOS was a top ten biotechnology company. Mr. Clark led the transition to a commercial organization achieving profitability while developing Cialis into a $ 1 billion product which became the market leader surpassing Viagra in many countries.
Paul has over 30 years of experience in the pharmaceutical and biotechnology industry. From 1984 to 1998, he worked in various capacities for Abbott Laboratories, a health care products manufacturer, retiring from Abbott Laboratories as Executive Vice President and Board member. In addition to other responsibilities during this time he ran the pharmaceutical business for fourteen years.
Mr.
Asha Rajagopal is the Acting Chief Financial Officer at Aldea Pharmaceuticals.
Asha Rajagopal joined the Aldea Pharmaceuticals management team as Acting CFO with 25 years of experience in public accounting and private industry, including work with small companies and large corporations.
Her biopharmaceutical industry experience includes heading the finance function at Genesoft Pharmaceuticals, where she participated in directing the reverse merger with Oscient Pharmaceuticals in 2004.
Ms. Rajagopal also held Senior Finance Positions at Cygent, Cambridge Management Consulting, Abbott Laboratories and Price Waterhouse.
Her expertise is small and large business finance and accounting processes, IPO support and accounting for merger and acquisitions.
Ms. Rajagopal received her BSBA in Accounting from the University of Texas and is a licensed CPA in California.
Don Wight is Chief Revenue Officer at PowerReviews, where he’s responsible for all our sales efforts. A veteran of enterprise sales and SaaS solutions, Don joins us from Jaspersoft, where he was Senior Vice President of Worldwide Field Operations, and delivered 32 straight quarters of record sales growth. Prior to Jaspersoft, Don was Vice President of Sales at Netcentives, where he helped the company to a successful IPO.
Dr. Kazumi Shiosaki began working with MPM in 2001 as an Entrepreneur-in-Residence while also holding the position of Senior Vice President of Scientific Development at Millennium Pharmaceuticals.
Since joining MPM full time in 2003, she has helped to found and served as the start-up CEO of several MPM portfolio companies including Primera Diagnostics and most recently Epizyme.
In addition, Dr. Shiosaki has played important advisory roles for Hypnion (where she was involved in the identification of the lead compound that lead to the sale of the company to Lilly in 2007), Oxagen and Aryx.
Dr. Shiosaki brings to MPM nearly 17 years of strategic and operational experience in the pharmaceutical-biotechnology industry with a career that began at Abbott Laboratories where she worked on drug discovery programs in a number of therapeutic areas including Neuroscience, Cardiovascular, and Infectious Disease.
Mr. Narajowski joined Roka Bioscience as SVP and General Manager of the San Diego operation.
He comes to Roka with over 25 years of experience in the business of life science. In the industry he is well known for his ability to take new technological concepts and turn them into successful businesses or major product lines.
Before joining Roka, Mr. Narajowski served from 2005 to 2008 as president, chief executive officer of Pathway Diagnostics, a biomarker development and testing company, which was sold to Quest Diagnostics.
Prior to Pathway, Mr. Narajowski served as vice president, general manager of Focus Diagnostics, an infectious disease reference laboratory and diagnostic product business. The majority of Mr.
Dr. Langer is a Director of Myriad Genetics, Inc., Myrexis, Inc., and several private health care companies. He has served as a Director of several public and private biotechnology, specialty pharmaceutical and diagnostic companies, including Sirna Therapeutics, Inc. (acquired by Merck & Co., Inc.), Ception Therapeutics, Inc. (acquired by Cephalon, Inc.), Transkaryotic Therapies, Inc. (acquired by Shire plc), Pharmacopeia, Inc. (acquired by Ligand, Inc.), and Cytogen Corporation (acquired by EUSA Pharma, Inc.). He was a Managing Partner at Phoenix IP Ventures, LLC from 2005-2010. From 2004-2005, he was President, North America for Dr.
Reddy’s Laboratories, Inc. Dr. Langer was with GlaxoSmithKline from 1994-2004, where he served as Senior Vice President, Project, Portfolio and Alliance Management, Senior Vice President, Product Development Strategy, and Senior Vice President, Healthcare Services R&D.
He also served as President and CEO at Neose Technologies, Inc. from 1991-1994.
Luann Pendy, Ph.D., is the Vice President of Global Quality. In this role, Luann oversees all global quality operations for the company. She joined Medtronic in 2008 as the Vice President of Corporate Quality.
Prior to Medtronic, Luann served as Corporate Vice President of Global Quality and Regulatory Affairs at Hospira, Inc. In that role, she led worldwide quality and regulatory affairs for the design and manufacturing of medical devices and pharmaceuticals. Previously, Luann spent 17 years at Abbott Laboratories, where she held several leadership roles in technical product development and quality for the diagnostics, devices and pharmaceutical business divisions.
Luann received her Bachelor of Science degree from the University of Michigan and her Doctorate of Philosophy in Immunology from Rush University in Chicago, Illinois.
Lori has worked in Manufacturing Engineering and Operations in the medical device industry for 25 years with experience in moving products from concept to commercialization.
Prior to joing EKOS she worked for Abbott Laboratories, Heart Technology, and Boston Scientific.
Lori has a Bachelor of Science degree in Chemical Engineering from Queens University in Kingston, Ontario.
Dr. Shalwitz co-founded Akebia in 2007 and is continuing on as Chief Medical Officer at Aerpio. He has principal responsibility for the development of AKB-4924. During the last 5 years with Akebia, Dr. Shalwitz brought AKB-6548 into Phase 2b for anemia. He was also very involved in the development of AKB-9778 for vascular leak, and bringing in federal and state grants to support the wound healing program for AKB-4924.
Prior to Akebia, Dr. Shalwitz was Vice President of Clinical Development at Reliant Pharmaceuticals, where he led a clinical team which launched and completed numerous clinical trials for the treatment of lipid and cardiac disorders, and contributed to several FDA filings.
Before Reliant, Dr. Shalwitz was Medical Director at Abbott Labs. During his 10-year tenure at Abbott Labs, Dr. Shalwitz’s team gained FDA approval for two NDAs (in lipid and cardiac disease). In addition, he acquired experience in all phases of drug development, from preclinical to Phase 4.
Eric has over 17 years of international sales and marketing experience in the medical device, trauma and orthopedic spine markets. Prior to joining DFINE, Eric held the position of Vice President of Commercial Operations for Europe, the Middle East and Canada at Kyphon International, a company focused on restoring spinal function through minimally invasive therapies. Before Kyphon, he held the position of International Sales Manager at Tutogen Medical Germany, where he was responsible for all sales activities in Europe and the Middle East.
Eric started his career as a sales representative at Abbott Germany selling medical devices and pharmaceutical products to hospitals before moving into the trauma and orthopedic markets, holding various positions with Synthes and Depuy in Germany.
Marc Beer is the Chief Executive Officer of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR).
Aegerion is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating often fatal, rare diseases. Marc took the company public in October 2010. The Companys first marketed product, JUXTAPID (lomitapide) was approved by the U.S. Food and Drug Administration in December 2012.
The company also has a Marketing Authorization Application for lomitapide under review in the EU. Marc brings over 20 years of development and commercialization experience in biotechnology, pharmaceuticals and diagnostics.
Ayyappan is the CTO of [YuMe](/company/yume).
Prior to co-founding YuMe in 2004, Ayyappan was Director of software development at Netopia, a publicly held manufacturer of DSL equipment and service provider for ISPs and carriers. Ayyappan was a co-founder of StarNet Technologies, a VoDSL company that was acquired by Netopia in 1999. Prior to co-founding StarNet, Mr. Sankaran held various technical positions in Octel communications (acquired by Lucent technologies), Abbott Labs, and Ready Systems.
Principal investor | General Manager | Strategic Advisor & Entrepreneur with 20 years of global professional experience.
Eugene Sun, M.D., joined Rib-X Pharmaceuticals in April 2013 as executive vice president, research and development.
Prior to joining Rib-X, Dr. Sun held multiple positions over a 17-year career at Abbott Laboratories (now Abbvie) where he most recently served as corporate vice president, global pharmaceutical clinical development.
In this role, he was responsible for the global clinical development, medical affairs, clinical operations and clinical pharmacology for all therapeutic areas of the pharmaceutical portfolio.
Prior to 2005, he held various leadership positions in the Abbott research and development organization with responsibility for several therapeutic areas, including anti-infectives, as well as pharmacovigilance, quality assurance, medical affairs and health economics and outcomes research.
During his tenure at Abbott, Dr.
William D. Shrader, PhD is the Senior Vice President of Innovation at Edison Pharmaceuticals, Inc.
Dr. Shrader obtained his BS in chemistry from the University of Illinois at Urbana and his PhD in organic chemistry from the University of California at Berkeley. Following his doctoral studies, Dr. Shrader was a National Institute of Health (NIH) postdoctoral fellow at the California Institute of Technology.
He has previously held positions at Abbott Laboratories, Celera Genomics, and Ampere Life Sciences, where he directed programs in thrombosis, oncology, and inflammation. His research expertise spans several fields, including medicinal chemistry, structure-based drug discovery, and enzymology.
Dr. Shrader is the author on more than 25 peer-reviewed journal articles in these fields.
Dr. Allen is the a co-founder, of Clovis Oncology, a NASDAQ-listed cancer therapeutics company with a focus upon drug and companion diagnostic development. Diagnostic partnerships have included Ventana, Roche Molecular Systems and Foundation Medicine. Previously he was Chief Medical Officer and EVP at Pharmion Corp,.
Pharmion also secured the approval in Europe of thalidomide for the front-line treatment of multiple myeloma patients ineligible for transplant.
Prior to Pharmion, Dr. Allen was Vice President Oncology Drug Development at Chiron, one of the original biotechnology companies in the Bay Area, which was acquired by Novartis.
Previously, Dr. Allen served as global project head in Abbott Laboratories’ oncology franchise, and prior to that he progressed through positions of increasing responsibility at McKinsey & Company, in the development and execution of business strategies for top-tier biotechnology and pharmaceutical companies, with a focus on oncology.
Dr.
Dr. Sasso joined Crescendo Bioscience in September 2012. He came to Crescendo from Abbott Laboratories, where as Medical Director, he worked in Early Immunology clinical development and in Humira Medical Affairs, both in Rheumatology and as head of the Dermatology team.
Prior to joining Abbott in 2004, he was Associate Professor at the University of Washington, Seattle, where he has remained an Adjunct Associate Professor since 2004.
Dr. Sasso earned an A.B. Biochemistry degree at Harvard University, Cambridge, MA, and an M.D. degree from the University of California, San Diego.
He trained in internal medicine at McGill University, Montreal, and did fellowships in rheumatology at the University of Washington, and in immunology research at the Virginia Mason Research Center, Seattle.
He is board certified in Internal Medicine and Rheumatology and has published extensively in the fields of rheumatology, immunology and dermatology.
Dr. joined Kalobios in May 2012 as our Chief Medical Officer. Dr. Molfino has over 18 years of experience in the biopharmaceutical industry. From July 2008 until he joined KaloBios, Dr. Molfino served as Vice President of Clinical Development, and Pulmonary Therapeutic Area Head of MedImmune. In this role, he was responsible for all phases of global clinical development for pulmonary conditions.
From 2004 to 2008, he was Senior Director, Clinical Development at Otsuka Maryland Research Institute.
Previously, he held the positions of Director, Medical Affairs at Baxter Bioscience from 2000 to 2003, and Vice President, R&D and Scientific Affairs at Theratechnologies, Inc., a Montreal-based biotechnology start-up. Earlier in his career in industry, Dr. Molfino was Director, Clinical Research at Abbott Laboratories and began his industry career at Boehringer Ingelheim.
Dr. Molino received his M.D.
Jim Keating is an Associate at IllinoisVENTURES primarily focused on the physical sciences. He brings a combination of chemistry and materials science expertise to the firm. He assists the firm in assessing new investment opportunities as well as managing existing portfolio companies. Prior to IllinoisVENTURES, Jim was an Analytical Chemist at Abbott Laboratories, working extensively with R&D and new product development. From there he served as an Analytical Consultant to a trust management partnership contributing grant monies for cancer research to worldwide organizations. Jim then joined a start-up consulting firm providing design and analysis services for companies looking to bring the latest technology into their design and manufacturing processes. Jim holds dual bachelors degrees in Biology and Chemistry from Valparaiso University, an MS in Materials Science and Engineering from the University of Texas, and an MBA from the University of Illinois at Urbana-Champaign.
Sue Washer, President and CEO of AGTC, is an experienced entrepreneur with a strong scientific and operational background. She has a B.S. in biochemistry from Michigan State University and an MBA from the University of Florida where she was one of the first graduates from the Business Schools Entrepreneurship program. Sue has 10 years of pharmaceutical management and research experience from Abbott Labs and Eli Lilly as well as 11 years of senior management experience with entrepreneurial firms in the Gainesville area. Sue successfully raised over $15M for AGTC in their second round of funding in November of 2003.
Jorge Artiles has more than 25 years experience in quality assurance and regulatory affairs in the medical device industry.
Prior to ATI he was Vice President Quality Assurance, Regulatory and Scientific Affairs, and Chief Quality Officer at ThermoGenesis.
Prior to ThermoGenesis, Jorge was Vice President of Quality Assurance and at Physio Control (a division of Medtronic), Cytyc Surgical Products, and Teleflex Medical. Prior to this, he held director level positions in quality assurance and quality systems at Abbott Laboratories and at Boston Scientific.
Jorges medical device experience began as Quality Engineering Manager at Target Therapeutics (now Boston Scientific) and Baxter Healthcare.
Mr. Artiles received a B.S. and a Masters Degree in Quality Assurance and Industrial Technology at San Jose State University.
Ms. Waterbury serves as Director of Quality at Savara.
Prior to Savara, Ms. Waterbury was responsible for Quality and Regulatory Compliance at Abbott Laboratories and has consulted with major drug, device, and combination product companies across the globe.
Ms. Waterbury is responsible for the oversight of Clinical Quality and GMP Manufacturing Operations including batch release, quality investigations, validation, quality training, and management of internal/external inspections.
Rebecca Waterbury holds a BE in Chemical Engineering and a Juris Doctorate (JD) of Law.
Mr. Kureshy has 35 years of experience in engineering, manufacturing, plant expansion and facility design, including 18 years with Abbott Labs in the Diagnostics Division where Mr. Kureshy held various management positions in production, industrial engineering, material flow operations, and facilities design and new plant start-up.
Mr. Kureshy holds a B.S. in electrical engineering and a B.S. in mathematics.
John Vozella joined T2 Biosystems in July, 2011; he brings over 30 years of experience in the medical device, diagnostic and pharmaceutical industries to the company.
Prior to joining T2 Biosystems, John served as V.P. Clinical & Regulatory Affairs at Interlace Medical where he led the companys regulatory, clinical and reimbursement initiatives resulting in successful commercial launch of the MyoSure Hysteroscopic Tissue Removal System and eventual acquisition of the company by Hologic, Inc.
Prior to joining Interlace, John was V.P. Regulatory Affairs, Clinical & Quality Assurance at NDO Surgical. He has held similar executive positions at Hologic, SomaLogic, Cadent Medical, Abbott Laboratories, MediSense and Kendall Healthcare. He has extensive experience establishing global regulatory strategies to support timely product introductions. He has designed and implemented clinical trials to obtain FDA clearance and reimbursement.
Mr. Chenet joined Liquidia in 2007 from Biolex Therapeutics where he was focused on executing new partnerships with pharmaceutical companies intent on leveraging Biolex’ protein engineering and production technology to enable new therapeutic protein products.
Prior to joining Biolex, Mr. Chenet was a Director in GlaxoSmithKline’s Worldwide Business Development where he was responsible for evaluating and negotiating worldwide licensing agreements across multiple therapeutics areas. Prior to GSK, Mr. Chenet spent several years as a manager at Abbott Laboratories.
Mr. Chenet has a M.B.A. from Stanford University and a B.S.E from the University of Michigan.
Division Director at Abbott Labs
Mr. Rohn has nearly 40 years of experience as a senior executive in the pharmaceutical and biotech industry.
Bill retired in January of 2005 from the position of Chief Operating Officer at Biogen-Idec, one of the larger global biotech companies, which was formed by the merger in 2003 of IDEC Pharmaceuticals and Biogen Inc.
Prior to serving as Chief Operating Officer of the combined company, Bill was the President and Chief Operating Officer of IDEC Pharmaceuticals, having joined the company in 1993 as Senior Vice President of Commercial and Corporate Development.
Before moving to the fledgling biotech industry in its early days, Bill spent approximately 25 years in the pharmaceutical sector in a variety of commercial operating roles of increasing responsibility with such companies as Abbott Laboratories, Bristol-Myers Squibb Co., and Adria Laboratories (now part of Pfizer).
Kathi Guerrant has over 25 years of clinical, regulatory, and quality assurance experience at medical device companies.
Prior to ATI she was Vice President of Clinical Affairs at Paracor, a medical device company creating novel, less-invasive solutions for the treatment of heart failure.
Prior to Paracor, Kathi was Vice President of Regulatory Affairs and Quality Assurance at Epicor Medical, a startup company developing tools to treat atrial fibrillation that was acquired by St. Jude Medical.
Prior, Kathi was with Ventritex, which was also acquired by St. Jude Medical, where she progressed from Senior Clinical Engineer to Director of Clinical Affairs.
Earlier in her career, she held clinical roles at Abbott Laboratories and Intermedics, Inc. Kathi is a named author on eight publications, seven of which involve devices currently used in the treatment of heart failure.
She received her Bachelor of Science degree in Bioengineering from Texas A&M University.
Prior Year Revenue | Current Year Revenue | Next Year Revenue |
---|---|---|
Sign up as Investor | Sign up as Investor | Sign up as Investor |
Company Age | Employees | Sub-Industry |
---|---|---|
26 years, 4 months | 66 | Other Biotechnology |
Company Type | Stock Exchange | Stock Symbol |
---|---|---|
Privately-Held | – | – |